BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 29774034)

  • 21. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
    Wada J; Suzuki H; Fuchino R; Yamasaki A; Nagai S; Yanai K; Koga K; Nakamura M; Tanaka M; Morisaki T; Katano M
    Anticancer Res; 2009 Mar; 29(3):881-8. PubMed ID: 19414323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
    Albini A; Bruno A; Noonan DM; Mortara L
    Front Immunol; 2018; 9():527. PubMed ID: 29675018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
    Paillasse MR; Esquerré M; Bertrand FA; Poussereau-Pomié C; Pichery M; Visentin V; Gueguen-Dorbes G; Gaujarengues F; Barron P; Badet G; Briaux A; Ancey PB; Sibrac D; Erdociain E; Özcelik D; Meneyrol J; Martin V; Gomez-Brouchet A; Selves J; Rochaix P; Battistella M; Lebbé C; Delord JP; Dol-Gleizes F; Bono F; Blanc I; Alam A; Hunneyball I; Whittaker M; Fons P
    Cancer Res Commun; 2022 Nov; 2(11):1504-1519. PubMed ID: 36970050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
    Strauss L; Volland D; Kunkel M; Reichert TE
    Med Sci Monit; 2005 Aug; 11(8):BR280-92. PubMed ID: 16049374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of anti-angiogenic drugs on regulatory T cells in the tumor microenvironment.
    Hu C; Jiang X
    Biomed Pharmacother; 2017 Apr; 88():134-137. PubMed ID: 28103506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.
    Kaumaya PT; Foy KC
    Future Oncol; 2012 Aug; 8(8):961-87. PubMed ID: 22894670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A; Libutti SK
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property.
    Kishuku M; Nishioka Y; Abe S; Kishi J; Ogino H; Aono Y; Azuma M; Kinoshita K; Batmunkh R; Makino H; Ranjan P; Minakuchi K; Sone S
    J Immunol; 2009 Dec; 183(12):8176-85. PubMed ID: 20007583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism.
    Baek YY; Lee DK; Kim J; Kim JH; Park W; Kim T; Han S; Jeoung D; You JC; Lee H; Won MH; Ha KS; Kwon YG; Kim YM
    Oncotarget; 2017 Feb; 8(7):11763-11777. PubMed ID: 28052029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells.
    Tian J; Ma J; Ma K; Guo H; Baidoo SE; Zhang Y; Yan J; Lu L; Xu H; Wang S
    Eur J Immunol; 2013 May; 43(5):1220-30. PubMed ID: 23424024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NKG2D-Fc fusion protein promotes antitumor immunity through the depletion of immunosuppressive cells.
    Feng PH; Lam B; Tseng SH; Kung YJ; Farmer E; Cheng MA; Hung CF
    Cancer Immunol Immunother; 2020 Oct; 69(10):2147-2155. PubMed ID: 32468232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. β-glucan restores tumor-educated dendritic cell maturation to enhance antitumor immune responses.
    Ning Y; Xu D; Zhang X; Bai Y; Ding J; Feng T; Wang S; Xu N; Qian K; Wang Y; Qi C
    Int J Cancer; 2016 Jun; 138(11):2713-23. PubMed ID: 26773960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.